Photo of Andrew D. Norden,  MD, MPH

Andrew D. Norden, MD, MPH

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2166
Fax: (617) 632-4773

Andrew D. Norden, MD, MPH

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Neurology, Harvard Medical School
  • Associate Neurologist, Neurology, Brigham And Women's Hospital
  • Neuro-Oncologist, Medical Oncology, Center for Neuro-Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am involved in the design and execution of clinical trials for patients with gliomas, meningiomas, and other tumors of the central nervous system. I have an interest in the treatment and prevention of seizures in brain tumor patients.

Publications

Powered by Harvard Catalyst
  • Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. 2015; 17:488-504. PubMed
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280-6. PubMed
  • Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. 2015. PubMed
  • Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J. Neurooncol. 2014. PubMed
  • Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. 2014; 16:567-78. PubMed
  • Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study. Epilepsy Res 2014. PubMed
  • Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J. Neurooncol. 2013; 115:267-76. PubMed
  • Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J. Neurooncol. 2013; 115:71-7. PubMed
  • Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer 2013; 119:3479-88. PubMed
  • Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. 2013; 15:930-5. PubMed
  • Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 2013. PubMed
  • Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. J. Neurooncol. 2012; 109:187-93. PubMed
  • Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS ONE 2012; 7:e38881. PubMed
  • Norden AD, Pope WB, Chang SM. Current concepts in brain tumor imaging. Am Soc Clin Oncol Educ Book 2014. PubMed
  • Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis. Oncologist 2011. PubMed
  • Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec(速) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J. Neurooncol. 2011. PubMed
  • Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol. 2011. PubMed
  • Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J. Neurooncol. 2010. PubMed
  • Sure D, Dunn I, Norden A, Anderson WS. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. Clin Neurol Neurosurg 2010; 112:741-2. PubMed
  • Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J. Neurooncol. 2010; 99:365-78. PubMed
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78:85-90. PubMed
  • Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol 2010; 12:321-33. PubMed
  • Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J. Neurooncol. 2010. PubMed
  • Wen PY, Norden AD, Drappatz J, Quant E. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 2010; 12:68-75. PubMed
  • Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J. Neurooncol. 2010; 96:211-7. PubMed
  • Wen PY,Yung WK,Lamborn KR,Norden AD,Cloughesy TF,Abrey LE,Fine HA,Chang SM,Robins HI,Fink K,Deangelis LM,Mehta M,Di Tomaso E,Drappatz J,Kesari S,Ligon KL,Aldape K,Jain RK,Stiles CD,Egorin MJ,Prados MD. Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro-oncol 2009; 11:853-60. PubMed
  • Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5:610-20. PubMed
  • Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-oncol 2009; 11:550-5. PubMed
  • Gerstner ER,McNamara MB,Norden AD,Lafrankie D,Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009; 94:97-101. PubMed
  • Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. 2009; 6:513-26. PubMed
  • Norden AD,Drappatz J,Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009; 9:231-40. PubMed
  • Norden AD,Drappatz J,Muzikansky A,David K,Gerard M,McNamara MB,Phan P,Ross A,Kesari S,Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2008; 92:149-55. PubMed
  • Drappatz J,Norden AD,Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 2009; 9:519-34. PubMed
  • Norden AD,Drappatz J,Ciampa AS,Doherty L,LaFrankie DC,Kesari S,Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro-oncol 2008; 11:92-5. PubMed
  • Kesari S,Schiff D,Drappatz J,LaFrankie D,Doherty L,Macklin EA,Muzikansky A,Santagata S,Ligon KL,Norden AD,Ciampa A,Bradshaw J,Levy B,Radakovic G,Ramakrishna N,Black PM,Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009; 15:330-7. PubMed
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2008; 73:222-7. PubMed
  • Norden AD,Drappatz J,Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7:1152-60. PubMed
  • Dietrich J,Norden AD,Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 2008; 21:736-44. PubMed
  • Norden AD,Drappatz J,Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol 2008; 20:652-61. PubMed
  • Bracht LK,Wen P,Meyerhardt JA,Kulke MH,Hornick JL,Redston M,LaFrankie DC,Black PM,Kesari S,Norden A,Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol 2008; 26:4843-4. PubMed
  • Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70:779-87. PubMed
  • Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin 2007; 25:1035-71, ix. PubMed
  • Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007; 7:1537-60. PubMed
  • Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus 2007; 23:E12. PubMed
  • Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie 2007; 30:90-1. PubMed
  • Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12:279-92. PubMed
  • Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol 2005; 18:654-61. PubMed
  • Blumenfeld H, McNally KA, Vanderhill SD, Paige AL, Chung R, Davis K, Norden AD, Stokking R, Studholme C, Novotny EJ, Zubal IG, Spencer SS. Positive and negative network correlations in temporal lobe epilepsy. Cereb Cortex 2004; 14:892-902. PubMed
  • Norden AD, Blumenfeld H. The role of subcortical structures in human epilepsy. Epilepsy Behav 2003; 3:219-231. PubMed
  • Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60:166-93. PubMed
Hide